A state-of-art review on camel milk proteins as an emerging source of bioactive peptides with diverse nutraceutical properties

• Published in: Food chemistry 2022-03, Vol.373 (Pt A), p.131444-131444, Article 131444
• Main Authors: Ali Redha, Ali, Valizadenia, Hamidreza, Siddiqui, Shahida Anusha, Maqsood, Sajid
• Format: Article
• Language: English
• Subjects: Animals; Antidiabetic; Antihypertension; Antioxidant; Bioactive peptides; Camel milk; Camelus; Dietary Supplements; Hydrolysates; Milk; Milk Proteins; Peptides
• ISSN: 0308-8146; 1873-7072
• DOI: 10.1016/j.foodchem.2021.131444

[Display omitted] •First systematic review on camel milk derived peptides (CM-BAPs) bioactivity based on 46 research articles.•CM-BAPs have shown significant α-amylase, α-glucosidase, and DPP-IV inhibition activities.•Vital anti-hypertensive potential of CM-BAPs has been reported through ACE-I inhibition.•Antioxidant, anti-diabetic, anti-hypertensive, antibacterial and anticancerous CM-BAPs sequences have been summarised.•More in-vivo evidence is required to evaluate the pharmacological potentials of CM-BAPs. The generation of camel milk derived bioactive peptides (CM-BAPs) have started to grab keen interest of many researchers during the past decade. CM-BAPs have shown more significant bioactive properties in comparison to camel milk intact proteins. CM-BAPs can be obtained using enzyme hydrolysis to form hydrolysates, or by the fermentation process. In this systematic review, 46 research articles exploring the health-related bioactive properties of CM-BAPs through in-vitro and in-vivo studies have been included. CM-BAPs have been reported for their antioxidant, anti-diabetic, anti-obesity, antihypertensive, antibacterial, antibiofilm, anticancer, anti-inflammatory, anti-haemolytic, and anti-hyperpigmentation activities. The effects of factors such as molecular weight of peptides, type of enzyme, enzyme to substrate ratio, hydrolysis temperature and duration have been analysed. The in-vitro studies have provided enough evidence on certain aspects of the pharmacological actives of camel milk bioactive peptides. Nevertheless, the in-vivo studies are very limited, and no clinical studies on CM-BAPs have been reported.